Ten thousand yuan childlike needle reduced to 999 yuan: Supply and demand reversal, medical and aesthetic companies reclaim pricing power from suppliers.

The era of upstream medical beauty supply chain manufacturers relying solely on controlling prices to maintain high profits may be gone forever. Recently, So-Young International announced cooperation with the first batch of 14 upstream manufacturers including Sota, Elken, Aimeike, Huaxi, Jinbo, and Sihuan Medicine. Many companies have had heated disputes with So-Young over pricing issues, and some suppliers even temporarily stopped supplying. However, it seems that the price war that lasted throughout last year has been temporarily paused with the conclusion of this cooperation. Many industry insiders believe that this reflects the restructuring of the power dynamics between the upstream and downstream of the medical beauty industry, and also heralds a major shift in the development logic of the entire industry.